EMA Application withdrawn: Lumevoq (lenadogene nolparvovec) — GenSight Biologics S.A.

View source ↗

Summary

The EMA withdrew the application for Lumevoq (lenadogene nolparvovec) by GenSight Biologics for Leber hereditary optic atrophy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leber Hereditary Optic Atrophy

Drugs mentioned

• Lumevoq (lenadogene nolparvovec)

Snippet

Status: Application withdrawn. Therapeutic area: Optic Atrophy, Hereditary, Leber. MAH: GenSight Biologics S.A.. Orphan medicine